Agora Financial - Breakthrough Technology Alert - PVCT excerpt
October 8, 2013
Excellent News From Our Biotech
Companies
Dear Breakthrough Technology Alert Reader,
Provectus Pharmaceuticals (OTCBB:PVCT)
has unveiled further data from its completed
Phase 2 trial in melanoma at the European
Cancer Congress 2013. If you recall, Provectus'
cancer compound, PV-10, is derived from a rosecolored
chemical dye first synthesized in 1882.
The presentation, called "Melanoma and Skin
Cancer," highlighted PV-10's ability to control
melanoma and recruit the immune system to act
on tumor cells. PV-10 not only reduced the size of
tumors directly injected with the compound, but
investigators also observed what's called the
"bystander effect." Other tumors, intentionally left
untreated, were also controlled. The immune
system is believed to be behind the effect, and
the theory is that rupturing tumor cells with PV-10
exposes the immune system to cancer antigens,
thereby training it to attack other cancer cells.
Some patients experienced blistering within a few
days of PV-10 administration. Furthermore,
patients who had this happen to them saw a
significantly higher percentage of best overall
responses to the therapy. In fact, 91% of patients
who blistered experienced stable disease or
better, versus 54% of patients who did not blister.
Again, it is very likely that the blistering is being
caused by an immune response. Therefore, it is
logical that patients with the strongest immune
responses, as evidenced by blistering, would also
have the best disease responses.
According to Dr. Craig Dees, Ph.D., CEO of
Provectus:
"The researchers concluded that PV-10 has a
unique immuno-chemoablative profile that offers
significant potential due to several important
attributes. First, its safety and efficacy compare
favorably with existing and emerging therapies.
Second, its safety profile makes it an attractive
candidate as a combination strategy for treatment
of advanced disease. And finally, it provides a
powerful combination of rapid reduction of tumor
burden with induction of tumor-specific immune
response that can achieve rapid disease control
in refractory patients with locally advanced
melanoma."
This is, of course, excellent news for Provectus.
The company is now prepping for a Phase 3
pivotal study.
Ad lucrum per scientia (toward wealth through
science),
Ray Blanco |
